Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Cagrilintide
Max Weight Loss0%
Studies8
Participants1,847
StatusLimited

Cagrilintide

Long-Acting Amylin Receptor Agonist

Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.

Complete Research Database

Clinical Research Outcomes

CagriSema Phase 3

Female, 43, BMI 35

Lost 52 pounds (24% body weight) in 68 weeks
“The combination therapy was remarkable - better appetite control than I ever experienced with semaglutide alone.”
Sustained weight loss with enhanced satiety and improved quality of life scores
Amylin Pathway Study 2023

Male, 51, Metabolic Syndrome

18% weight loss with improved gastric emptying
“Food satisfaction improved dramatically - I felt full with smaller portions and stayed satisfied longer.”
Significant improvements in gastroparesis symptoms and metabolic parameters
Phase 2 Monotherapy Trial

Female, 39, Pre-diabetes

Prevented diabetes progression, 15% weight loss
“Six months later, still maintaining weight loss and my A1C is completely normal.”
Excellent tolerability with gradual dose escalation protocol

Clinical Outcome Measures

+68.4
🍽️ Appetite Control
(from 12.3 baseline)
+15.6
⚖️ Weight Reduction
(from 0 baseline)
+42.7
🍯 Glucose Control
(from 8.1 baseline)
+35.8
😊 Quality of Life
(from 47.2 baseline)
+51.3
🕒 Meal Satisfaction
(from 32.6 baseline)
Clinical outcome measures

Cardiovascular & Metabolic Outcomes

Blood Pressure Reduction

-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs

Triglycerides

-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement

HDL Cholesterol

+8.3% increase
Statistical significance: p<0.01
Improved lipid profile

Waist Circumference

-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity

C-Reactive Protein

-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation

Sleep Apnea Events

-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation

Medical Disclaimer

This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.